Efficacy and Safety of SKB264 in Combination With Pembrolizumab in Patients With Initially Unresectable Stage III NSCLC

NCT ID: NCT06706219

Last Updated: 2024-12-10

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 50 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-03-31
• Study Completion Date: 2029-05-31

Brief Summary

This study is a phase 2 open-label, multicenter clinical study to evaluate the efficacy and safety SKB264 in combination with pembrolizumab in patients with unresectable stage III non-small cell lung cancer.

Detailed Description

This study is a phase 2 open-label, multicenter clinical study to evaluate the efficacy and safety SKB264 in combination with pembrolizumab in patients with unresectable stage III non-small cell lung cancer. The study includes a screening period (up to 28 days after the subject signs the informed consent form until before the first dose), a treatment period (including an induction treatment period, a local treatment period (surgery or radical radiotherapy), and a consolidation treatment period), and a follow-up period (including two parts of safety follow-up and survival follow-up).

Approximately 50 patients with initially unresectable stage III non-small cell lung cancer patients, without EGFR/ALK/ROS-1-sensitive mutations, without chest radiotherapy and systemic anti-tumor therapy, were enrolled and treated with Sacituzumab tirumotecan (SKB264) in combination with pembrolizumab until disease progression, intolerable toxicity, or meeting the criteria for discontinuation of the trial drug.

The primary endpoint is the investigator-assessed 18-month progression-free survival (PFS) rate of intention-to-treat population (ITT). Secondary endpoints include event-free survival (EFS), overall survival (OS), R0 surgical resection rate, complete response (pCR) rate, major pathological response (MPR) rate and safety, objective response rate (ORR) in the induce treatment period. Recruitment for the study is expected to begin in mainland China around January 2025, with the trial anticipated to conclude in January 2028.

Conditions

Non Small Cell Lung Cancer (Stage III)

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Sacituzumab tirumotecan (SKB264) in combination with pembrolizumab

Group Type: EXPERIMENTAL

Sacituzumab tirumotecan plus pembrolizumab

Intervention Type: DRUG

Participants meeting the inclusion criteria will receive pembrolizumab 200 mg IV on D1, Q3W + SKB264 4mg/kg IV on D1, D15 and D29，Q2W for 12 weeks as induction therapy.

Subjects who receive radical radiotherapy will undergo 8 cycles of pembrolizumab 200 mg IV on D1, Q3W; For those receiving surgical treatment, pembrolizumab is selected for adjuvant therapy for pCR patients, and SKB264 combination with pembrolizumab is selected non-PCR patients.

Interventions

Sacituzumab tirumotecan plus pembrolizumab

Participants meeting the inclusion criteria will receive pembrolizumab 200 mg IV on D1, Q3W + SKB264 4mg/kg IV on D1, D15 and D29，Q2W for 12 weeks as induction therapy.

Subjects who receive radical radiotherapy will undergo 8 cycles of pembrolizumab 200 mg IV on D1, Q3W; For those receiving surgical treatment, pembrolizumab is selected for adjuvant therapy for pCR patients, and SKB264 combination with pembrolizumab is selected non-PCR patients.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• 1.Patients who voluntarily participate in this clinical study, understand the study procedures and are able to sign the informed consent form in writing;
• 2.Men or women aged 18-70 years (inclusive) at the time of signing the informed consent form.
• 3.ECOG PS score of 0 or 1.
• 4.Histologically or cytologically confirmed stage III squamous cell or non-squamous cell non-small cell lung cancer that cannot be surgically treated as determined by the investigator. Disease staging should be based on the American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) NSCLC staging system, 8th edition.
• 5.Ability to provide tumor tissue specimens, either archived within 6 months prior to the first dose of study drug or freshly obtained. See the laboratory manual for specific requirements.
• 6.Pulmonary function of at least FEV1 > 1.0 L and FEV1% > 40% within 3 months.
• 7.Patients must have measurable target lesions examined by CT or MRI per RECIST v1.1 criteria. Tumor imaging assessments are performed within 28 days prior to the first dose.
• 8.Adequate hematologic and vital organ functions, as defined by the following laboratory findings, which need to be completed within 14 days prior to the first study treatment:

1. Hematology (no hematopoietic stimulating factor drugs or blood transfusion within 14 days before the first study treatment): absolute neutrophil count (ANC) ≥ 1.5 × 109/L, absolute lymphocyte count (LC) ≥ 0.5 × 109/L; platelet count (PLT) ≥ 100 × 109/L, hemoglobin (Hb) ≥ 90 g/L

2. Liver function: aspartate transferase (AST) and alanine aminotransferase (ALT) ≤2.5 x ULN; ; serum total bilirubin (TBIL) ≤ 1.5 x ULN (total bilirubin ≤ 3.0 mg/dL in patients with confirmed Gilbert syndrome); albumin (ALB) ≥ 3 g/dL;

3. Renal function: creatinine clearance rate (CrCl) ≥ 45 mL/minute (by Cockcroft-Gault formula);

4. Coagulation: international normalized ratio (INR) ≤ 1.5, activated partial thromboplastin time (APTT) ≤ 1.5 x ULN;

5. Cardiac color ultrasound: left ventricular ejection fraction (LVEF) ≥ 50%

• 9.Female patients of childbearing potential must have a negative pregnancy test (serum or urine) within 72 hours prior to receiving the study drug. Reliable contraception, such as intrauterine devices, oral contraceptives, or condoms, must be used during the trial and for 90 days following the final dose. Male participants with partners of childbearing potential must use condoms during the trial and for 30 days following the studys conclusion

Exclusion Criteria

• 1.Histologically or cytologically confirmed mixed SCLC and NSCLC, large cell neuroendocrine carcinoma and sarcomatoid carcinoma;
• 2.Patients with positive EGFR mutations or ALK gene rearrangements. All patients must undergo EGFR gene testing and ALK gene and/or immunohistochemistry testing；
• 3.Presence of malignant pleural effusion. If a patient has a extractable pleural effusion during the screening period, at least one thoracentesis must be performed to confirm whether there are malignant tumor cells;
• 4.Patients who have received any systemic anti-tumor therapy for NSCLC, including surgical treatment, local radiotherapy, cytotoxic drug therapy, targeted therapy, immunotherapy, or traditional Chinese medicine (excluding patients who had other malignancies that were radically resected and have remained recurrence-free for more than 5 years);
• 5.Diagnosis of any other cancer within 5 years prior to enrollment, except for carcinoma in situ of the cervix, cured basal cell carcinoma, or bladder epithelial tumors (including Ta and Tis);
• 6.Patients with active autoimmune diseases or a history of autoimmune conditions, such as uveitis, enteritis, hepatitis, hypophysitis, vasculitis, myocarditis, nephritis, hyperthyroidism, or hypothyroidism (the latter is allowed if controlled by hormone replacement therapy), or tuberculosis. Note: Patients with a history of childhood asthma that has completely resolved and has not required treatment in adulthood may be included. Patients with skin conditions (e.g., vitiligo, psoriasis, or alopecia) that do not require systemic therapy are also eligible;
• 7.Patients with current or prior history of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-induced pneumonitis, radiologically confirmed active pneumonitis, or severe pulmonary impairment;
• 8.Patients who have received systemic corticosteroids (prednisone >10 mg/day or equivalent) or other immunosuppressive medications within 2 weeks prior to the first dose. Inhaled or topical corticosteroids and adrenal replacement therapy are allowed if there is no evidence of active autoimmune disease, and the dose of prednisone is less than 10 mg/day;
• 9.Known hypersensitivity to the investigational drug or any of its components;
• 10.Patients who are active carriers of hepatitis B, hepatitis C, or HIV;
• 11.Pregnant or breastfeeding women;
• 12.Patients of childbearing potential who are unwilling or unable to use effective contraception. Additionally, patients with a history of neurological or psychiatric disorders who demonstrate poor treatment compliance;
• 13. Any other condition that, in the investigator's opinion, makes the patient unsuitable for participation in the study

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Hunan Province Tumor Hospital

OTHER

Sponsor Role: lead

Responsible Party

Yongchang Zhang

Director, Head of Medical Oncology, Principal Investigator, Clinical Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Hunan Provincal Tumor Hospital

Changsha, Hunan, China

Countries

China

Central Contacts

Yongchang Zhang, MD

Role: CONTACT

Phone: +8613873123436

Email: zhangyongchang@csu.edu.cn

Facility Contacts

Yongchang Zhang, MD

Role: primary

Other Identifiers

NeoTrop

Identifier Type: -

Identifier Source: org_study_id